Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Influenza
Interventions: Inactivated Influenza H1N1 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: COVID-19
Interventions: AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: Healthy Volunteers
Interventions: HSV529, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Inflammatory Response
Interventions: Pneumovax 23, Typhim VI, Saline; Drug · Other
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Lyme Borreliosis
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more

Conditions: Duchenne Muscular Dystrophy
Interventions: AVI-4658 (Eteplirsen), Placebo; Drug · Other
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 7 Years to 13 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections
Interventions: VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, FFB, PBS; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 3 more

Conditions: Influenza, Human
Interventions: D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 470 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more

Conditions: Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Shigellosis
Interventions: bacteriophage, Placebo; Biological · Other
Lead sponsor: Intralytix, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Agitation, Anesthesia, Pediatrics
Interventions: Dexmedetomidine, Saline; Drug
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 6 Months to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: AVX101, placebo; Biological · Other
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 6
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: HS110 vaccine, Placebo; Biological
Lead sponsor: Heat Biologics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Influenza
Interventions: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 10
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Influenza
Interventions: A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia), Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 841 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 10
States / cities: Denver, Colorado • Chicago, Illinois • Metairie, Louisiana + 7 more

Conditions: Seasonal Influenza
Interventions: Influenza VLP Vaccine, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Pembroke Pines, Florida • Baltimore, Maryland

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 5 Years to 55 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Encephalitis
Interventions: MVA-BN-WEV, Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Sacramento, California • Lilburn, Georgia • Lenexa, Kansas + 6 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: SARS-CoV-2
Interventions: Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose; Drug · Biological
Lead sponsor: Sean Liu; Other
Eligibility: 18 Years to 59 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Alopecia
Interventions: Hair Stimulating Complex (HSC), Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Volunteers
Interventions: Questionnaire, Stool sample, Skin swab, Oral rinse; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Persistent Readiness Through Early Prediction Immunization Study

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis

Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry